gBRCA MUTATIONS CAN OCCUR IN A VARIETY OF PATIENTS WITH mBC

Now we know it’s not just younger patients or patients with TNBC or a family history of BRCA-related cancers who have gBRCA mutations.1,2

Real-world analyses confirm gBRCA mutations occur in more patient types than you might expect

Retrospective analysis of 225 US patients with gBRCA-mutated HER2- mBC showed1*:

72%

had HR+/HER2-
disease

39%

were aged >55 years

17%

were African-American or
of Asian or Hispanic descent†

Retrospective analysis of 177 US patients with gBRCA-mutated HER2- ABC showed2‡:

28%

had no known family history of BRCA-related cancers

Majority of patients with HER2- mBC have HR+/HER2- disease3

SEER population-based analysis including 5590 US patients with HER2- mBC showed3§:

82%

had HR+/HER2- disease

pie chartpie chart
18%

had triple-negative disease

Observational real-world analysis assessing 341 US/non-US patients with
HER2- mBC for gBRCA mutations showed4||:

  • A similar prevalence of gBRCA mutations in patients with metastatic
    HR+/HER2- and triple-negative breast cancer (9.3% vs 9.2%)4

A variety of patients may have gBRCA mutations, so testing all patients with recurrent BC or mBC can help inform treatment planning1,2,5

ABC=advanced breast cancer; BC=breast cancer; BRCA=breast cancer susceptibility gene; gBRCA=germline breast cancer susceptibility gene; HER2-=human epidermal growth factor receptor 2 negative; HR+=hormone receptor-positive; mBC=metastatic breast cancer; SEER=Surveillance, Epidemiology and End Results; TNBC=triple-negative breast cancer.

References: 1. Quek RGW, Mardekian J. Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with germline BRCA1/2 mutation: a real-world retrospective study. Adv Ther. 2019;36(3):708-720. 2. Parikh RC, Niyazov A, Esterberg E, et al. Patient demographics, clinical characteristics, and treatment patterns among patients with germline breast cancer susceptibility gene 1/2 mutated HER2- advanced breast cancer: results from a US real-world study. Poster presented at: Miami Breast Cancer Conference; March 5-8, 2020; Miami, FL. Poster 46. 3. Gong Y, Liu Y-R, Ji P, Hu X, Shao Z-M. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep. 2017;7:45411. 4. O'Shaughnessy JO, Brezden-Masley C, Cazzaniga M, et al. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020;22(1):114. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer. V.4.2022. June 21, 2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed June 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.